IL2 and cancer: Specifically, IFN-α, a representative FDA-approved cytokine has been used in the clinic to treat leukemia since 1986, and subsequently, recombinant interleukin-2 (IL-2) has been developed for cancer immunotherapy since 1992 59-61.